Abstract
Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Keywords: Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes, rehabilitation.
Current Respiratory Medicine Reviews
Title:Management of Stable COPD: An Update
Volume: 9 Issue: 6
Author(s): Alexandru Corlateanu, Gloria Montanari, Alexandros G. Mathioudakis, Victor Botnaru and Nikolaos Siafakas
Affiliation:
Keywords: Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes, rehabilitation.
Abstract: Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Export Options
About this article
Cite this article as:
Corlateanu Alexandru, Montanari Gloria, G. Mathioudakis Alexandros, Botnaru Victor and Siafakas Nikolaos, Management of Stable COPD: An Update, Current Respiratory Medicine Reviews 2013; 9 (6) . https://dx.doi.org/10.2174/1573398X10666140222001646
DOI https://dx.doi.org/10.2174/1573398X10666140222001646 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments in Anti-dotes Against Anthrax
Recent Patents on Anti-Infective Drug Discovery Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Metabolic Evidence of Diminished Lipid Oxidation in Women With Polycystic Ovary Syndrome
Current Metabolomics Modified LDL Immune Complexes and Cardiovascular Disease
Current Medicinal Chemistry Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry Perioperative Considerations in Patients with Obstructive Sleep Apnea
Current Respiratory Medicine Reviews Pharmacotherapy for Premature Ejaculation
Current Drug Therapy Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) The Role of Essential Oils and the Biological Detoxification in the Prevention of Aflatoxin Borne Diseases
Current Topics in Medicinal Chemistry Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease
Current Enzyme Inhibition The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review
Current HIV Research η-Secretase: Reduction of Amyloid Precursor Protein η-Site Cleavage in Alzheimers Disease
Current Alzheimer Research Protein-Tyrosine Kinases and Adaptor Proteins in FcεRI-Mediated Signaling in Mast Cells
Current Molecular Medicine The Cellular Effects of Carbon Monoxide in the Airway
Current Molecular Medicine Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Fc Receptor Signaling in Leukocytes: Role in Host Defense and Immune Regulation
Current Immunology Reviews (Discontinued) Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry